{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:35:38Z","timestamp":1790670938816,"version":"4.1.0"},"reference-count":83,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Minimal residual disease (MRD) detection is established routine practice for treatment stratification in leukemia and used for treatment optimization in adult lymphomas. Minimal disease studies in childhood non-Hodgkin lymphomas are challenged by stratified treatment in different subtypes, high cure rates, low patient numbers, limited initial tumor material, and early progression. Current clinical applications differ between the subtypes. A prognostic value of minimal disseminated disease (MDD) could not yet be clearly established for lymphoblastic lymphoma using flow cytometry and PCR-based methods for T-cell receptor (TCR) or immunoglobulin (IG) rearrangements. MYC\u2013IGH fusion sequences or IG rearrangements enable minimal disease detection in Burkitt lymphoma and -leukemia. An additional prognostic value of MDD in Burkitt lymphoma and early MRD in Burkitt leukemia is implicated by single studies with risk-adapted therapy. MDD and MRD determined by PCR for ALK-fusion transcripts are independent prognostic parameters for patients with ALK-positive anaplastic large cell lymphoma (ALCL). They are introduced in routine clinical practice and used for patient stratification in clinical studies. Early MRD might serve as an endpoint for clinical trials and for guiding individual therapy. Validation of MDD and MRD as prognostic parameters is required for all subtypes but ALCL. Next-generation sequencing-based methods may provide new options and applications for minimal disease evaluation in childhood lymphomas.<\/jats:p>","DOI":"10.3390\/cancers13081907","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T12:11:00Z","timestamp":1618488660000},"page":"1907","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Minimal Disease Monitoring in Pediatric Non-Hodgkin\u2019s Lymphoma: Current Clinical Application and Future Challenges"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4802-1866","authenticated-orcid":false,"given":"Lara","family":"Mussolin","sequence":"first","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Clinic of Pediatric Hemato-Oncology, University of Padova, 35128 Padova, Italy"},{"name":"Istituto di Ricerca Pediatrica, Fondazione Citt\u00e0della Speranza, 35127 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Damm-Welk","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pillon","sequence":"additional","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, Clinic of Pediatric Hemato-Oncology, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Woessmann","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2005.05735.x","article-title":"The impact of age and gender on biology, clinical features and treatment outcome of non-hodgkin lymphoma in childhood and adolescence","volume":"131","author":"Burkhardt","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2008.18.1487","article-title":"Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: Results of a randomized trial of the EICNHL group","volume":"27","author":"Brugieres","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3324\/haematol.2015.139162","article-title":"Results and conclusions of the European intergroup euro-LB02 trial in children and adolescents with lymphoblastic lymphoma","volume":"102","author":"Landmann","year":"2017","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Auperin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2014.59.5827","article-title":"Non-Hodgkin lymphoma in children and adolescents: Progress through effective collaboration, current knowledge, and challenges ahead","volume":"33","author":"Brugieres","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjh.15793","article-title":"Lymphoblastic lymphoma in children and adolescents: Review of current challenges and future opportunities","volume":"185","author":"Burkhardt","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_7","first-page":"1124","article-title":"Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM-type first-line therapy","volume":"135","author":"Woessmann","year":"2020","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hon.2069","article-title":"XI. How to treat children and adolescents with relapsed non-Hodgkin lymphoma?","volume":"31","author":"Woessmann","year":"2013","journal-title":"Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1200\/JCO.20.00157","article-title":"Stem cell transplantation and vinblastine monotherapy for relapsed pediatric anaplastic large cell lymphoma: Results of the international, prospective ALCL-relapse trial","volume":"38","author":"Knorr","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1182\/blood-2016-12-725804","article-title":"Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia","volume":"129","author":"Campana","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/asheducation-2014.1.244","article-title":"Detection and management of minimal residual disease in acute lymphoblastic leukemia","volume":"2014","author":"Schrappe","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies","volume":"125","author":"Bruggemann","year":"2015","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.14996","article-title":"Minimal residual disease in non-hodgkin lymphoma\u2014Current applications and future directions","volume":"180","author":"Chase","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2017.74.5281","article-title":"Minimal residual disease assessment in lymphoma: Methods and applications","volume":"35","author":"Herrera","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2014.59.7203","article-title":"Revised international pediatric non-Hodgkin lymphoma staging system","volume":"33","author":"Rosolen","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/j.jpedsurg.2008.08.046","article-title":"Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma","volume":"43","author":"Kuroda","year":"2008","journal-title":"J. Pediatr. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large b-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: A correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1200\/JCO.2003.03.006","article-title":"Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor","volume":"21","author":"Schleiermacher","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1158\/1078-0432.CCR-15-2516","article-title":"Impact of two measures of micrometastatic disease on clinical outcomes in patients with newly diagnosed ewing sarcoma: A report from the children\u2019s oncology group","volume":"22","author":"Vo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.V72.6.1891.1891","article-title":"Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: A pediatric oncology group study","volume":"72","author":"Crist","year":"1988","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2008.21.1318","article-title":"Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: A report from the children\u2019s oncology group","volume":"27","author":"Sandlund","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/pbc.25607","article-title":"Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience","volume":"62","author":"Mussolin","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pbc.21823","article-title":"Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR)","volume":"52","author":"Stark","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2015.203","article-title":"Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia","volume":"30","author":"Balbach","year":"2016","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1182\/blood-2012-12-474148","article-title":"Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence","volume":"121","author":"Bonn","year":"2013","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1200\/JCO.2011.39.7661","article-title":"Clinical impact of notch1 and\/or fbxw7 mutations, flash deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma","volume":"30","author":"Callens","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","article-title":"Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells","volume":"79","author":"Bregni","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/sj.leu.2402828","article-title":"Prospective analysis of minimal bone marrow infiltration in pediatric Burkitt\u2019s lymphomas by long-distance polymerase chain reaction for t(8;14)(q24;q32)","volume":"17","author":"Mussolin","year":"2003","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1200\/JCO.2010.32.8161","article-title":"Minimal disseminated disease in high-risk Burkitt\u2019s lymphoma identifies patients with different prognosis","volume":"29","author":"Mussolin","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.14240","article-title":"Detection of prognostic factors in children and adolescents with Burkitt and diffuse large B-cell lymphoma treated with the AIEOP LNH-97 protocol","volume":"175","author":"Pillon","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_32","first-page":"818","article-title":"Combined polymerase chain reaction methods to detect c-myc\/igh rearrangement in childhood Burkitt\u2019s lymphoma for minimal residual disease analysis","volume":"89","author":"Busch","year":"2004","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/labinvest.2009.81","article-title":"IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt\u2019s lymphoma and mature B-all MRD analysis","volume":"89","author":"Lovisa","year":"2009","journal-title":"Lab. Investig."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the biomed-2 concerted action BMH4-CT98-3936","volume":"17","author":"Langerak","year":"2003","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"412163","DOI":"10.1155\/2009\/412163","article-title":"Screening for residual disease in pediatric Burkitt lymphoma using consensus primer pools","volume":"2009","author":"Agsalda","year":"2009","journal-title":"Adv. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/bjh.13443","article-title":"Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: A children\u2019s oncology group pilot study report","volume":"170","author":"Shiramizu","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1200\/JCO.2007.11.3159","article-title":"Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood","volume":"25","author":"Mussolin","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1111\/bjh.16531","article-title":"Minimal residual disease analysis in childhood mature B-cell leukaemia\/lymphoma treated with AIEOP LNH-97 protocol with\/without anti-CD20 administration","volume":"189","author":"Mussolin","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2141.2009.07754.x","article-title":"Distribution of NPM1-ALK and X-ALK fusion transcripts in paediatric anaplastic large cell lymphoma: A molecular-histological correlation","volume":"146","author":"Klapper","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1200\/JCO.2011.36.5411","article-title":"Prognostic impact of morphologic and phenotypic features of childhood alk-positive anaplastic large-cell lymphoma: Results of the ALCL99 study","volume":"29","author":"Lamant","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, alk, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2005.05808.x","article-title":"Childhood anaplastic large cell lymphoma has a high incidence of alk gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: A genetic and pathological correlation","volume":"131","author":"Perkins","year":"2005","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Montes-Mojarro, I.A., Steinhilber, J., Bonzheim, I., Quintanilla-Martinez, L., and Fend, F. (2018). The pathological spectrum of systemic anaplastic large cell lymphoma (ALCL). Cancers (Basel), 10.","DOI":"10.3390\/cancers10040107"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2007-02-066852","article-title":"Prognostic significance of circulating tumor cells in bone marrow or peripheral blood as detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive anaplastic large-cell lymphoma","volume":"110","author":"Busch","year":"2007","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/sj.leu.2403888","article-title":"Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma","volume":"19","author":"Mussolin","year":"2005","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2013-09-526202","article-title":"Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma","volume":"123","author":"Mussolin","year":"2014","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12185-017-2338-6","article-title":"Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma","volume":"107","author":"Mori","year":"2018","journal-title":"Int J. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/leu.2012.205","article-title":"Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis","volume":"27","author":"Mussolin","year":"2013","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Mussolin, L., Le Deley, M.C., Carraro, E., Damm-Welk, C., Attarbaschi, A., Williams, D., Burke, A., Horibe, K., Nakazawa, A., and Wrobel, G. (2020). Prognostic factors in childhood anaplastic large cell lymphoma: Long term results of the international ALCL99 trial. Cancers (Basel), 12.","DOI":"10.3390\/cancers12102747"},{"key":"ref_50","first-page":"2141","article-title":"Quantification of minimal disseminated disease by quantitative PCR and digital PCR for NPM-ALK as prognostic factor in children with anaplastic large cell lymphoma","volume":"105","author":"Kutscher","year":"2019","journal-title":"Haematologica"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lowe, E.J., Reilly, A.F., Lim, M.S., Gross, T.G., Saguilig, L., Barkauskas, D.A., Wu, R., Alexander, S., and Bollard, C.M. (2021). Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ALCL: Results of COG trial ANHL12P1. Blood, online ahead of print.","DOI":"10.1182\/blood.2020009806"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2141.2007.06672.x","article-title":"Flow cytometric detection of circulating tumour cells in nucleophosmin\/anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: Comparison with quantitative polymerase chain reaction","volume":"138","author":"Schieferstein","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Rigaud, C., Abbas, R., Grand, D., Minard-Colin, V., Aladjidi, N., Buchbinder, N., Garniere, N., Plat, G., Couec, M.-L., and Duplan, M. (2021). Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?. Pediatr. Blood Cancer, Online ahead of print.","DOI":"10.1002\/pbc.28982"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1511045","article-title":"Abrupt relapse of ALK-positive lymphoma after discontinuation of crizotinib","volume":"374","author":"Mussolin","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"607","DOI":"10.7326\/L16-0037","article-title":"Nivolumab for refractory anaplastic large cell lymphoma: A case report","volume":"165","author":"Hebart","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A children\u2019s oncology group phase 1 consortium study","volume":"14","author":"Mosse","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","article-title":"Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: A children\u2019s oncology group study","volume":"35","author":"Mosse","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41375-019-0413-0","article-title":"Standardisation and consensus guidelines for minimal residual disease assessment in philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1","volume":"33","author":"Pfeifer","year":"2019","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/leu.2014.217","article-title":"A certified plasmid reference material for the standardisation of BCR-ABL1 MRNA quantification by real-time quantitative PCR","volume":"29","author":"White","year":"2015","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Dube, S., Qin, J., and Ramakrishnan, R. (2008). Mathematical analysis of copy number variation in a DNA sample using digital PCR on a nanofluidic device. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002876"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Sanders, R., Mason, D.J., Foy, C.A., and Huggett, J.F. (2013). Evaluation of digital PCR for absolute RNA quantification. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075296"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1073\/pnas.96.16.9236","article-title":"Digital PCR","volume":"96","author":"Vogelstein","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Whale, A.S., Cowen, S., Foy, C.A., and Huggett, J.F. (2013). Methods for applying accurate digital PCR analysis on low copy DNA samples. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0058177"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jmoldx.2020.11.002","article-title":"Minimal residual disease monitoring using a 3\u2019ALK universal probe assay in ALK-positive anaplastic large-cell lymphoma: DDPCR, an attractive alternative method to real-time quantitative PCR","volume":"23","author":"Quelen","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"ref_68","first-page":"173","article-title":"Mapping of genomic t(2;5)(p23;q35) break points in patients with anaplastic large cell lymphoma by sequencing long-range PCR products","volume":"11","author":"Luthra","year":"1998","journal-title":"Hematopathol. Mol. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1182\/blood.V88.5.1771.1771","article-title":"Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin\u2019s lymphomas, Hodgkin\u2019s disease, or lymphomatoid papulosis","volume":"88","author":"Sarris","year":"1996","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"26543","DOI":"10.18632\/oncotarget.25489","article-title":"Characterization and diagnostic application of genomic NPM-ALK fusion sequences in anaplastic large-cell lymphoma","volume":"9","author":"Krumbholz","year":"2018","journal-title":"Oncotarget"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-019-0257-x","article-title":"Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor all","volume":"9","author":"Alawi","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.18632\/oncotarget.13741","article-title":"Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer","volume":"8","author":"Cui","year":"2017","journal-title":"Oncotarget"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kunimasa, K., Kato, K., Imamura, F., and Kukita, Y. (2019). Quantitative detection of ALK fusion breakpoints in plasma cell-free DNA from patients with non-small cell lung cancer using PCR-based target sequencing with a tiling primer set and two-step mapping\/alignment. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0222233"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"65208","DOI":"10.18632\/oncotarget.11569","article-title":"Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11899-018-0468-4","article-title":"Updates on circulating tumor DNA assessment in lymphoma","volume":"13","author":"Darrah","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/bmt.2016.227","article-title":"Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-cell lymphomas","volume":"51","author":"Gauthier","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Attarbaschi, A., Abla, O., Arias Padilla, L., Beishuizen, A., Burke, G.A.A., Brugieres, L., Bruneau, J., Burkhardt, B., d\u2019Amore, E.S.G., and Klapper, W. (2020). Rare non-Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma. Pediatr. Blood Cancer, 67.","DOI":"10.1002\/pbc.28416"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12967-019-2114-x","article-title":"Circulating micrornas as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia","volume":"17","author":"Rzepiel","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Drandi, D., Alcantara, M., Benmaad, I., Sohlbrandt, A., Lhermitte, L., Zaccaria, G., Ferrante, M., Genuardi, E., Mantoan, B., and Villarese, P. (2020). Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the European MCL network. Hemasphere, 4.","DOI":"10.1097\/HS9.0000000000000347"},{"key":"ref_83","first-page":"56","article-title":"Quality control of standardized methods for NPM-ALK RT-PCR and anti-ALK-antibody measurement for anaplastic large cell lymphoma\u2014A report of the EICNHL reference laboratory group","volume":"171","author":"Yamashita","year":"2015","journal-title":"Br. J. Haematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/8\/1907\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:48:26Z","timestamp":1760161706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/8\/1907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":83,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["cancers13081907"],"URL":"https:\/\/doi.org\/10.3390\/cancers13081907","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,15]]}}}